In vitro drug-induced cardiotoxicity determination is a key step in clinical drug discovery. For this reason, the use of cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) is promising. However, the ability of a single hiPSC-CM to mimic natural heart tissue in structure and function is limited, and the use of hiPSC-CM to generate artificial heart tissue has always been a challenge. Therefore, researchers have developed a new method of constructing three-dimensional (3D) artificial tissues in a short period of time by coating extracellular matrix (ECM) components on the cell surface. It is hypothesized that 3D heart tissue derived from hiPSC-CMs (3D-hiPSC-CT) can be used for in vitro drug-induced cardiotoxicity determination. 3D-hiPSC-CT is generated from a single hiPSC-CM coated with fibronectin and gelatin nanomembrane.
By providing a high-throughput functional system to test the safety and efficacy of the heart, to screen and identify compounds or pathways that may change the physiology and pathology of the heart, Creative Bioarray has become a leading developer of human 3D cell and tissue culture models. The high-content analysis of ergonomic tissue facilitates drug discovery in the screening and optimization phase of potential customers. Creative Bioarray's proprietary technology enables engineered tissues to grow in 3D to mimic healthy and disease-free human tissues, which can bridge the gap between cell-based assays and research using isolated organs, tissues, or animal models. Engineered tissues developed without a synthetic support layer can be physiologically measured (such as shrinkage) and analyzed.
Human induced pluripotent stem cell (iPSC) technology is essential in precision medicine because it produces disease models in petri dishes. The ability of iPSCs to produce large numbers of pluripotent cells that can differentiate into almost any somatic cell type is attractive. However, achieving this feat industrially is daunting, because a well-defined, uniform and reproducible patient-derived iPSC is essential for celI to differentiate into somatic cells and develop tissues and organs for faithful disease modeling. The automation of iPSC culture can standardize and standardize cell proliferation. Allows researchers to process large numbers of human cell lines. In addition, the personalized 3D human heart tissue model enables researchers to use a rich research population for drug safety and efficacy analysis in the preclinical stage.
Differences in ion channel composition and signal cascades between species may hinder the predictability of cardiotoxicity tests through the use of non-human experimental models. However, the traditional 2D cell culture model cannot generalize the structure and organization of myocardium in humans, and lacks the key process of cardiomyocyte differentiation. Moreover, conventional static 2D culture of adult muscle cells cannot preserve the adult phenotype.
In order to overcome the weaknesses and limitations of current cell-based and animal-based tests, a 3D model with appropriate biophysical tissue structure is generated for cardiotoxicity testing in order to provide highly predictive and detailed information for human in vivo research. Creative Bioarray provides the opportunity for highly predictable preclinical cardiotoxicity testing to help customers reduce the cost and time of bringing new drug candidates to the market.
Creative Bioarray uses a series of concentrations to test the target compound, focusing on a wide range of test endpoints, including: QT interval, pulsation rate change, contraction rate and duration, and the compound's effect on different ion channels, so that customers can better characterize the compound.